oral glp-1 agonists New Guidelines for Type 2 Diabetes in 2025 Dosage of GLP-1 analogues |
Description
doi: 10.1111/j.1467-789X.2004.00144.x 8 BlherM
Access this article Similar content being viewed by others References Nissen SE, Wolski K
Evidence is also accumulating in Parkinsons disease, where GLP-1RAs have shown neuroprotective actions
Hepatology 41(6):13131321
However, we did require that patients had a prescription fill of the GLP-1 RA and had a reason for discontinuation
But obesity can cause many diseases
